SPIRIVA HANDIHALER
LAMA DPI
Tiotropium bromide · Boehringer Ingelheim
Active Medication & Mechanism
- Tiotropium bromide monohydrate LAMA18 mcg per capsule (delivers 10 mcg from mouthpiece)
Long-acting muscarinic antagonist (anticholinergic). Binds to M1–M3 muscarinic receptors, with slow dissociation from M3 receptors on airway smooth muscle, providing 24-hour bronchodilation.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 18 mcg | Adults (≥18 years) | 2 inhalations of 1 capsule once daily (entire capsule content) Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations. | 18 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Spiriva HandiHaler is NOT indicated for asthma. Use Spiriva Respimat for asthma (different product and dose). |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not for acute bronchospasm. Use a SABA. |